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Abstract
Background: Poor adherence to medication in schizophrenia spectrum disorders leads to inadequate symptom
control. Adherence therapy (AT) is an intervention that seeks to reduce patients’ psychiatric symptoms by enhancing
treatment adherence. We aimed to systematically review the trial evidence of the effectiveness of AT on improving
clinical outcomes in these patients.
Method: Systematic review and meta-analysis of published RCTs. We included studies testing AT as an adjunct
intervention against treatment as usual or a comparator intervention in the general adult psychiatric population.
The primary outcome of interest was improvement in psychiatric symptoms.
Results: We included six studies testing AT in schizophrenia spectrum disorders published since 2006. A meta-analysis
showed AT significantly reduced psychiatric symptoms compared to usual treatment over a follow-up period of less
than 1 year. We found no significant effects of AT on patients’ adherence and adherence attitudes.
Conclusions: AT is an effective adjunctive treatment for people with schizophrenia spectrum disorders.
Prospero: CRD42015016779
Keywords: Schizophrenia, Adherence therapy, Compliance, Adherence, Systematic review, Meta-analysis,
Schizophrenia-spectrum disorders
Background
Maintenance treatment with antipsychotic medication
is important for patients with schizophrenia [1]. Adher-
ence to antipsychotic treatment is often poor; between 41
and 61 % of patients do not take medication as prescribed
[2, 3]. Non-adherence can have serious consequences,
including poor symptom control and an increased risk of
relapse [4]. Effective interventions that have the potential
to improve medication adherence may improve patients’
clinical outcomes.
Adherence therapy (AT) is a brief psychological inter-
vention based on the principles of motivational inter-
viewing (MI) and cognitive behavioural therapy (CBT).
It was developed by Gray et al. [5] building on the work
of Kemp et al. [6]. AT is a patient-centred approach nor-
mally delivered by trained clinicians over a series of 8
weekly sessions. Key therapy techniques include medica-
tion problem solving, exchanging information, exploring
ambivalence, and challenging beliefs. Theoretically, these
techniques amplify the personally relevant benefits of treat-
ment, modify illness and treatment beliefs, and resolve
ambivalence towards taking medication. The National In-
stitute for Health and Care Excellence (NICE) [7] and the
World Health Organization (WHO) [8] in their adherence
guidelines review and advocate an approach to enhance
adherence that concords well with AT. In particular, this
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should involve adapting the consultation style to the
patients’ individual needs, establishing the most effect-
ive way of communicating with patients, encouraging
patients to ask about their condition and treatment,
and asking patients open-ended questions [7]. The
NICE [9] and BAP (British Association for Psychopharma-
cology) [10] schizophrenia guidelines specifically recom-
mend that AT is not used, creating a contradiction in the
guideline recommendations.
The efficacy of AT on symptom outcomes has not
been systematically studied. One previous systematic
review by Hegedüs and Kozel [11] examined the effect-
iveness of AT on adherence. The review authors did not
evaluate the effect of AT on symptoms and were not
able to complete a meta-analysis because of missing data
[12]. The aim of this systematic review was to determine
the effectiveness of AT in addition to usual care on
symptom severity and other outcomes in patients with
schizophrenia spectrum disorders, when compared to
treatment as usual alone or in combination with an ac-
tive control. Symptom improvement is the focus of this
review, primarily because a focus on improving adher-
ence has previously been described as meaningless if
patients’ clinical outcomes remain unimproved [13].
Other reasons for focusing on psychiatric symptoms in-
clude the widely-reported problems encountered when try-
ing to accurately measure adherence and the fact that the
majority of AT trials were powered to detect changes in
symptoms, rather than treatment adherence [12]. Our sec-
ondary aim was to test the effects of AT on other patient
outcomes, including adherence behaviour and attitudes.
Methods
We adhered to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines for
reporting the results of systematic reviews [14]. We regis-
tered the protocol for this review with the Prospero
International Prospective Register of Systematic Reviews
(http://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42015016779 number PROSPERO 2015:
CRD42015016779).
Search strategy
We conducted an electronic search of MEDLINE
(1961–2015), Cumulative Index to Nursing and Allied
Health (CINAHL with Full Text) (1904–2015), The
Cochrane Library (1900–2015), EMBASE (1947–2015),
PubMed and Scopus. The search strategy to identify
relevant papers involved a MESH (or INDEXTERM)
term ‘schizophrenia’ and keyword ‘adherence therapy’,
combined using ‘and’ to identify papers reporting the
effectiveness of ‘adherence therapy’ as described by Gray
et al. [5] in patients with schizophrenia (see Additional
file 1 for details). We also hand searched the reference
lists from the included published articles to identify
potentially relevant papers. We also contacted recent
key authors to enquire about potential grey literature.
Inclusion and exclusion criteria
Types of studies
We included all randomised controlled trials (RCTs) test-
ing the effectiveness of adherence therapy (AT) [5] as an
adjunct intervention with treatment as usual (TAU), com-
pared with TAU or an active control. Studies were included
if they were written in English and published between
January 2006 (when AT was first described) and July 2015.
We included studies with varying follow-up periods.
Types of participants
Participants with a formal diagnosis of schizophrenia
spectrum disorders, including schizoaffective and schizo-
phreniform disorders according to the criteria of Diag-
nostic and Statistical Manual, DSM-IV-TR [15] were
included. Participants were aged 18 years or older. We
included studies testing the effectiveness of adherence
therapy within the general population of people with
schizophrenia or related disorders. We excluded studies
that focused on forensic patients because the additional
legal restrictions and requirements for compulsory treat-
ment may have influenced patients’ attitudes towards
treatment. This would complicate direct comparisons of
results within a general psychiatric setting. The study
settings involved inpatients or outpatients treated in the
community, who were receiving approved usual treat-
ment for schizophrenia or other related disorder.
Intervention and control conditions
We included RCTs published between January 2006 and
July 2015 that tested the effectiveness of adherence ther-
apy alone or as an adjunct therapy with TAU in people
with schizophrenia spectrum disorders. Control condi-
tions could either involve TAU, placebo or an active
control treatment.
Primary and secondary outcomes
The primary outcome in this review was psychiatric
symptoms and secondary outcomes were medication ad-
herence and adherence attitudes. Studies were included
if they reported data for either the primary or the sec-
ondary outcomes, using validated quantitative question-
naires or other validated measures.
Study selection and data extraction
The abstracts of studies identified from the search
process were screened for eligibility by AI and DB inde-
pendently. Papers with unclear eligibility were resolved
by discussion. Full text articles were then obtained and
read in detail independently by AI, DB and RG. The
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characteristics of studies viewed as being ineligible for
inclusion were recorded in addition to the reasons for
exclusion. All studies that reported the means and SDs
of the areas of patient outcomes for the treatment and
control groups were included in the meta-analyses.
Where these figures were not available, attempts were
made by DB and RG to obtain them from the re-
searchers concerned. Data extracted from the studies
included methodological information, descriptions of the
experimental and control intervention, outcomes and
their measures, statistical methods, length of follow-up,
and description of the populations and setting(s). Data
from studies was extracted independently by AI and DB
and compared to eliminate errors.
Risk of bias in individual studies and across studies
The studies included in this review were assessed for
their quality using the Cochrane Collaborations’ risk of
bias assessment tool [16].
We have potential conflicts of interest as we have been
closely involved in conducting the included studies,
therefore the risk of bias assessments were carried out
by an external expert in systematic reviews, in addition
to being assessed independently by members of the
research team. The external reviewer’s scores and rea-
sons for these were discussed at length in order to reach
an objective consensus view. In case of queries, we con-
tacted the trials’ authors to provide more information.
We aimed to use the risk of bias assessments to context-
ualise the level of evidence for the review as a whole and
highlight potential common biases across studies. The
bias assessment was not used to determine the studies’
inclusion.
Summary measures
In order that the results of the various studies could be
compared and contrasted we calculated Hedges’ adjusted
g standardised mean differences (SMD) and the 95 %
confidence intervals (CI) for each of the clinical out-
comes using Review Manager 5.3 software [17]. This
was calculated as the difference between the means of
the treatment and control condition at each post-test,
divided by the pooled standard deviation.
Synthesis of results
Due to the apparent degree of heterogeneity in terms of
outcome measures used we conducted meta-analyses
with SMDs using a random-effects model. The effect
sizes for each study were pooled according to the model.
We calculated I2 as an indication of the percentages of
heterogeneity of pooled effect sizes, and tested the
significance of heterogeneity using the Q statistic. The
outcome assessment tools used in the studies measured
three distinct areas of patient outcomes; symptoms,
adherence attitudes and adherence behaviours. We
therefore conducted a separate meta-analysis for each in
line with recommendations from Higgins et al. [16]. We
calculated overall effect sizes and 95 % CIs to estimate
the intervention effects.
Results
Study selection
Figure 1 shows the results of the literature search within
a PRISMA flow diagram.
Initially, 76 records were identified. After removing du-
plicates, 41 potential papers remained, of which four were
excluded due to being published before the cut-off date
(2006). Screening the remaining 37 papers’ abstracts and
titles narrowed down the numbers of potential papers to
14. Of these, eight were excluded; the reasons for exclud-
ing papers were: commentary articles (n = 1), studies not
reporting an RCT of adherence therapy (n = 5), one study
involved patients within a forensic secure hospital, and
one study did not report psychiatric symptoms as a study
outcome. Six studies fulfilled the inclusion criteria for this
review. One of the studies (Chien et al. [18]) reports out-
comes at 6-month follow-up. We understand from the
author that 12-month follow-up data will be reported in
due course. We have only included the published data in
this meta-analysis.
Study characteristics
Table 1 shows the study characteristics and results of the
studies included in the review.
Participants
Participants’ baseline characteristics are shown in Table 1.
The six included studies involved a total of 725 patients
and were conducted internationally. Participants were
patients with a diagnosis of schizophrenia or related
psychosis such as schizoaffective disorder. Their mean age
ranged between 23 and 41 years and in all studies the ma-
jority were male (range between 57 and 79 %). Anderson
et al. [19] and Chien et al. [18] included outpatients with
schizophrenia or other psychotic disorders, the remaining
studies focused on inpatients with community follow up.
Only one study explicitly focused on recruiting non-
adherent patients (Chien et al. [18]). Gray et al. [5]
reported that approximately 30 % of their sample was
non-adherent. Patients were deemed mostly adherent in
two trials [5] and [20].
Study designs
Four of the six studies included in this review were de-
scribed as being single-blind RCTs. Two (Anderson et al.
[19] and Maneesakorn et al. [21]) were exploratory RCTs
based on the definition from the MRC framework for the
evaluation of complex interventions [22]. The follow-up
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period in the studies varied considerably, ranging between
several days in Anderson et al. [19] and 1 year in Gray et al.
[5], after completion of the intervention.
Interventions
The experimental intervention in all six studies was ad-
herence therapy. The control intervention in five studies
was described as treatment as usual (TAU), which varied
across studies, potentially due to their different settings.
Only Gray et al. [5] offered didactic health education as
control treatment in addition to TAU. Health education
was provided in the same number and duration of ses-
sions as was provided for the experimental treatment
in order to control for the effect of the non-specific ef-
fects of time spent with health professionals [5]. Both
AT and health education in this study were provided
by the same therapists. Brief descriptions of TAU are
shown in Table 1.
Outcome measures
Table 2 shows the intervention outcomes for each in-
cluded study. The numbers of participants for some areas
Fig. 1 Prisma flow diagram of studies in the review
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Table 1 Characteristics of studies included in the review
Reference Study location Sample and setting Interventions Total participants N
analysed at follow-up
(intervention/control)
Baseline characteristics
(intervention/control)
Number and duration
of AT sessions
Follow up (attrition rate
intervention/control)
Anderson et al.
(2010) [19]
United States Outpatients; diagnosis
of schizophrenia or
schizoaffective disorder
aged >18
AT + TAU/TAU (day treatment,
case management, employment
placement, medication monitoring
and individual counselling)
N = 23 (10/13) Mean age 29 (13),
range 21–57 in AT/
31–62 years in TAU;
79 % male
Not reported Within several days of
completion (17 %/7 %)
Chien et al.
(2015) [18]
Hong Kong Outpatients; diagnosis of
schizophrenia or other
psychotic disorder within
past 5 years; poor adherence
(DAI score <11), recent
non-adherence,
aged 18–64
AT + TAU/TAU (routine treatment:
psychiatric consultations at the
two outpatient clinics, home visits
by a community psychiatric nurse,
brief education on psychiatric
treatment and referrals to
healthcare and welfare services)
N = 110 (54/56) Mean age 29.21 (9.64)
in AT/28.13 (8.96) in
TAU; 51 % male in
AT/53 % male in TAU
Mean n of AT
sessions 6.9 (1.0)
6 months (3.5 %)
Gray et al.
(2006) [5]
Amsterdam,
Leipzig, London
and Verona
Inpatients and community
setting; diagnosis of
schizophrenia; evidence
of clinical instability in
previous year;
AT + TAU/TAU + didactic health
education
N = 371 (175/196) Mean age 40.9 years
(11.7) in AT/42.1 (11.4)
years in TAU; 60 % male
Mean n of sessions
7 (1.96) in AT/7 (2.49)
in TAU; mean duration
36 (12.1) min in AT/30
(9.9) min in TAU
52 weeks (12.7 %/5.4 %)
Maneesakorn
et al. (2007)
[21]
Chiang Mai,
Thailand
Inpatients with community
follow up; diagnosis of
schizophrenia, aged >20
AT + TAU/TAU (standard care:
medication treatment, occupational
therapy, group counseling and
recreational therapy)
N = 28 (14/14) Mean age 38.7 (12.8)
years in AT/43 (6.5)
years in TAU; 81 %
male in AT/61 %
male in TAU
All (14) received 8
sessions of AT;
mean duration
43.68 (6.24) mina
9 weeks (12.5 %/12.5 %)
Schulz et al.
(2013) [20]
Germany: Bielefeld,
Warstein, Lippstadt;
Switzerland: Bern
Inpatients; aged >18,
schizophrenic disorder
and inpatient in
participating ward
AT+ TAU/TAU (based on national
guidelines; including medication,
psychotherapy, occupational
therapy and psycho-education)
N = 123 (72/51) Mean age 35 (10)
years; 60 % male in
AT/56 % male in TAU
Mean number of
sessions 7.24 (1.09;
5–9); mean duration
of sessions 42 min
(12.96; 17–92 min)
12 weeks
Von Bormann
et al. (2015)
Thailand Inpatients due to psychiatric
exacerbation; aged >20,
schizophrenia diagnosis
AT + TAU/TAU (medication,
vocational and recreational
therapy and outreach
community psychiatric support)
N = 70 (38/32) Mean age 38 (11) years
in AT/40 (9) years in
TAU; 71 % male in
AT/78 % male in TAU
All received 8 sessions
of AT; mean duration
41 (8.0) min
26 weeks
Total N = 725 (363/362)
Abbreviations: N number of participants, AT adherence therapy, TAU treatment as usual, DAI Hogan drug attitude inventor
areported in Maneesakorn [39], a PhD thesis. Maneesakorn et al. [21] and Maneesakorn [39] reported the findings of the same study and are included as a single study in the review
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of outcome are less than the total number in each trial
due to missing data at follow-up.
Psychiatric symptoms were measured using the Positive
and Negative Syndrome Scale (PANSS [23]) in five of the
six studies. Only Gray et al. [5] assessed psychiatric symp-
toms using the Brief Psychiatric Rating Scale (BPRS [24]).
Adherence attitudes were assessed in all six studies. One
study [5] used the Schedule for Assessment of Insight –
Compliance item (SAI-C [25]), two (Maneesakorn et al.
[21] and von Bormann et al. [26]) used the Hogan
Drug Attitude Inventory (DAI [27]); one (Anderson
et al. [19]) used the Personal Evaluation of Transi-
tions in Treatment scale (PETiT [28]) and one (Chien
et al. [18]) used the Insight and Treatment Attitude
Questionnaire (ITAQ [29]).
Adherence behaviour was assessed in three studies.
Chien et al. [18] measured adherence using the Adherence
Rating Scale (ARS [30]) that combines the ratings of two
professionals. Gray et al. [5] used a self-rating scale Medi-
cation Adherence Questionnaire (MAQ [31]). Schulz et al.
[20] evaluated patients’ adherence using an objective
measure of medication concentration to dose ratio (CDR),
in addition to patients’ self-rated adherence using the
Medication Adherence Rating Scale (MARS [32]).
Risk of bias across included studies
Figures 2 and 3 detail the overall risk of bias and the
bias assessment of individual studies.
We were able to obtain confirmation from the site co-
ordinators, data analysts and co-investigators regarding
bias risk issues through personal communication, but we
decided that we would adopt a conservative and more
objective approach towards all bias assessments by bas-
ing our scores on documentary evidence rather than
personal report.
The study with the highest risk of bias included in this
review was that conducted by Anderson et al. [19]; we
decided that this study had an unknown risk of bias in
most assessment areas except low risks of bias for “ran-
dom sequence generation” and “blinding of outcome
assessments”, but a high risk of potential for “other bias”.
Issues that could indicate a high risk of “other bias”
include an inadequately powered sample size, the follow-
up being conducted immediately post-intervention and
the high refusal/non response rate (80 %) of potential
participants. Two studies (Gray et al. [5] and Chien et al.
[18]) were judged to have the lowest risk of bias because
the papers reported the selection process of participants
and blinding issues in sufficient detail, in addition to
Table 2 Intervention outcome
Intervention group Control group Effect size
Study Outcome
measures
n Baseline
mean (SD)
Follow-up
mean (SD)
n Baseline
mean (SD)
Follow-up
mean (SD)
SMD (95 % CI)
Anderson et al. (2010) [19] PETiT 10 40.10 (9.24) 37.30 (8.87) 13 40.10 (10.29) 41.61 (8.63) −0.48 (−1.31, 0.36)
PANSS 10 74.60 (13.79) 64.40 (30.54) 13 81.2 (17.66) 72.53 (19.20) −0.32 (−1.15, 0.51)
Chien et al. (2015) [18] PANSS 54 80.19 (11.10) 68.12 (14.81) 56 81.13 (12.01) 83.45 (14.13) −1.05 (−1.45, −0.65)
ITAQ 54 9.12 (6.14) 13.88 (6.80) 56 9.33 (3.31) 9.79 (6.21) 0.62 (0.24, 1.01)
ARS 54 1.48 (0.98) 3.08 (1.24) 56 1.39 (1.01) 1.48 (1.01) 1.41 (0.99, 1.83)
Gray et al. (2006) [5] SAI-C 173 5.04 (1.39) 5.22 (1.57) 189 4.73 (1.63) 5.03 (1.55) 0.12 (−0.08, 0.33)
MAQ 172 2.98 (1.24) 3.20 (1.07) 194 2.97 (1.20) 3.33 (1.02) −0.12 (−0.33, 0.08)
BPRS 175 45.96 (13.23) 38.11 (11.33) 196 44.31 (12.79) 37.34 (9.79) 0.07 (−0.13, 0.28)
Maneesakorn et al.
(2007) [21]
DAI-30 14 19.19 (6.96) 21.63 (5.91) 14 15.38 (9.82) 13.50 (7.58) 1.16 (0.35, 1.97)
SWAM 14 116.81 (26.83) 126.50 (18.40) 14 115. 13 (20.79) 113.19 (19.12) 0.71 (−0.02, 1.40)
PANSS 14 56.81 (10.86) 41.63 (10.33) 14 61.25 (15.58) 60.06 (13.94) −1.46 (−2.31, −0.61)
Schulz et al. (2013) [20] CDR 54 3.83 (6.80) 3.34 (5.36) 39 4.19 (5.79) 6.36 (10.56) −0.38 (−0.79, 0.04)
DAI-30 69 22.46 (6.83) 22.70 (6.59) 46 22.70 (6.69) 22.83 (5.89) −0.02 (−0.39, 0.35)
MARS 69 7.55 (2.07) 7.75 (2.01) 46 7.46 (1.73) 7.65 (1.87) 0.03 (−0.35, 0.40)
PANSS 63 48.32 (13.83) 44.13 (10.67) 42 49.33 (14.74) 50.29 (13.67) −0.51 (−0.91, −0.11)
von Bormann et al. (2015) DAI-30 38 15.74 (8.85) 20.11 (4.79) 32 15.91 (7.69) 18.91 (7.24) 0.20 (−0.27, 0.67)
PANSS 38 46.76 (16.06) 43.13 (13.92) 32 48.19 (16.05) 48.50 (15.42) −0.36 (−0.84, 0.11)
Abbreviations: ARS adherence rating scale [30], BPRS brief psychiatric rating scale [24], CDR concentration to dose ratio, DAI Hogan drug attitude inventory [27],
ITAQ insight and treatment attitude questionnaire [29], MAQ medication adherence questionnaire [31], MARS medication adherence rating scale [32], PANSS
positive and negative syndrome scale [23], PETiT personal evaluation of transitions in treatment scale [28], SAI-C schedule for assessment of insight – compliance
item [25]
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accounting for any missing data and having enough in-
formation provided to determine a low risk of potential
selective reporting.
All included studies presented a low risk of bias asso-
ciated with random sequence generation because each
study provided sufficient details about the methods
used, or referred to an external randomisation service
being used. We were therefore able to adequately deter-
mine that the process should have theoretically pro-
duced comparable groups. Allocation concealment was
also generally well-described in all studies, except for
Anderson et al. [19].
Due to the psychosocial nature of the AT intervention
it was not feasible or possible for any of the participants
or therapists involved in the included studies to be truly
blinded to treatment allocation. This issue, in conjunc-
tion with a reliance on patient-reported outcome mea-
sures in the majority of studies is likely to present a risk
of largely unavoidable participant performance bias and
has resulted in us scoring four studies as an unclear risk
of bias in this area ([19–21, 26]). The Gray et al. [5] and
Chien et al. [18] studies were felt to have a “low” risk of
performance bias when viewed within the context of the
nature of the intervention tested. Gray et al. [5] reported
that although participants would have been aware if they
were receiving AT or health education, they were
masked to which of the interventions was intended to be
the control intervention. Chien et al. [18] used some
more objective outcome measures in relation to levels of
adherence and rates of re-hospitalizations. However,
most studies, except Anderson et al. [19] provided
enough details to ascertain that outcome assessors were
blinded to treatment allocation.
The risk of reporting bias in two studies (Anderson
et al. [19] and Maneesekorn et al. [21]) was rated as “un-
clear” because the treatment protocols were not published
on an online trial registry and full details of participant
attrition/exclusion were not reported in the papers.
All of the six studies were felt to have (at best) an un-
known risk of “other bias” due to a range of reasons which
included the use of treatment-as-usual as a control inter-
vention (which does not account for the potential non-
specific benefits of contact with therapists) and uncertainty
that some studies established therapist fidelity to the man-
ualised treatment. Unfortunately, high rates of refusal are
common when conducting adherence studies. People who
are non-adherent appear to be inherently less likely to
agree to participate in research studies, resulting in poten-
tial selection bias and the recruitment of generally adherent
participants [33].
Results of individual studies
Table 2 outlines the results of each outcome area for in-
dividual studies. Of the six included studies, three found
AT to significantly improve patients’ clinical outcomes
compared to treatment as usual (TAU) (Chien et al. [18],
Maneesakorn et al. [21] and Schulz et al. [20]) and the
Fig. 3 Risk of bias in each study included
Fig. 2 Overall risk of bias
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other three studies found no significant differences. Two
RCTs (Chien et al. [18] and Maneesakorn et al. [21])
showed significant improvement of patients’ adherence
attitudes in the AT group compared to TAU. Of the
three studies reporting adherence behaviours as an out-
come, only Chien et al. [18] found a significant effect of
AT over TAU.
Effects of interventions
We compared the effects of adherence therapy and con-
trol treatment on three outcomes of the individual studies:
1) psychiatric symptoms, 2) medication adherence and 3)
adherence attitudes.
Adherence therapy vs. control treatment on psychiatric
symptoms
All six studies reported the effects of AT and control treat-
ment on patients’ psychiatric symptoms. Figure 4 shows
the results of random-effects meta-analysis for the com-
parison of ATand control treatment on patients’ psychiatric
symptoms, indicating a relatively high level of heterogeneity
among the studies (I2 = 86 %; n = 6; 707 participants). Five
studies found positive effects of AT over control treatment;
and three of them were statistically significant (Chien et al.
[18], Maneesakorn et al. [21] and Schulz et al. [20]). The
meta-analysis of the pooled data showed a significant im-
pact of AT on patients’ psychiatric symptoms with a SMD
of −0.56 (95 % CI −1.03, −0.09; 707 participants) and effect
size Z = 2.33 at p = 0.02.
Adherence therapy vs. control treatment on adherence
attitudes
All six studies reported a change in patients’ adherence
attitudes. Figure 5 shows the results of random-effects
meta-analysis comparing the effects of AT and control
treatment on patients’ adherence attitudes. The overall
effect (Z = 1.61) was not significant but favourable for
AT, with the SMD 0.25 (95 % CI −0.05; 0.55). Between-
study heterogeneity in adherence attitudes was consider-
able (I2 = 66 %; n = 6; 708 participants).
Adherence therapy vs. control treatment on adherence
behaviour
Figure 6 shows the results of random-effects meta-analysis
comparing AT and control intervention in patients’ adher-
ence behaviours, which were reported in three of the stud-
ies (Chien et al. [18], Gray et al. [5] and Schulz et al. [20]).
Between-study heterogeneity was high with I2 = 95 % (n =
3; 591 participants). The overall effect (Z = 0.98) suggests a
favourable but non-significant trend for AT.
Discussion
The aim of this systematic review was to evaluate the ef-
fectiveness of adherence therapy (AT) [5] on the psychi-
atric symptoms of patients with schizophrenia and related
disorders. We identified six randomised controlled trials
that mainly compared the effects of AT with TAU on pa-
tients’ psychiatric symptoms, medication adherence and
adherence attitudes. We found that AT had significantly
more positive effects on patients’ symptoms than TAU,
but not on adherence behaviours and attitudes.
This is the first systematic review and meta-analysis
evaluating the effects of adherence therapy on symptom
outcomes in schizophrenia. The benefits of AT on pa-
tient outcomes are consistent with studies not included
in this review, reporting that AT could reduce relapse
rates in early psychosis [34] and/or improve psychiatric
symptoms and adherence in forensic patients diagnosed
with schizophrenia [35].
This review provides novel and important evidence
that AT can improve psychiatric symptoms when com-
pared to usual treatment. Our observation is not consist-
ent with the current NICE [9] and BAP [10] guidance,
which has concluded that AT should not be offered as a
specific intervention for people with schizophrenia. Our
meta-analysis of six RCTs demonstrated that AT could
improve patients’ psychiatric symptoms, although the
improvement in symptoms was less than the recom-
mended clinically significant reduction of 20 % [36].
While the recommended reduction of 20 % was based
on drug trials [36], we reviewed the effectiveness of a
psychological therapy (AT) administered as an adjunct
intervention. Its aim was to maximise the effects of
usual treatment, rather than to act as a stand-alone
Fig. 4 Comparison of the effects of the AT and TAU on psychiatric symptoms
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intervention. In addition, in most of the included studies
(except for Chien et al. [18]) the patients were notably
less unwell than those included in many drug trials as
they were only mild-moderately ill at the start of the AT
interventions. The inclusion of mild-moderately ill partici-
pants in AT studies clearly leaves less room for potential
improvement of symptoms. However, it is possible that a
further reduction in symptoms of <20 % would be clinic-
ally meaningful and have a positive effect on patients’
outcomes.
The only trial where control treatment included an
active contact with a therapist was Gray et al. [5] who
provided didactic health education in combination with
TAU. This was provided by the same therapists, poten-
tially creating a significant risk of cross-contamination
of therapeutic technique and effects. On the other hand,
potential risk of bias by additional therapeutic contact
was introduced in the other five studies where the con-
trol treatment involved only TAU. The overall risk of
bias in the included studies was judged as mostly low or
unclear. Consequently, even though there might be
plausible bias that would influence the outcomes, this
was not considered at a level that would seriously affect
the overall findings. There was no obvious link between
study quality and outcome. The two most methodologic-
ally robust trials Gray et al. [5] and Chien et al. [18] re-
ported different outcomes. The trial that was rated to have
the highest risk of bias [19] reported no effect of AT.
We found no significant benefit of AT over usual
treatment on adherence attitudes and behaviour. This
observation is not consistent with the findings of AT tri-
als that are not included in this review. For example, in
a forensic sample, Cavezza et al. [35] found significant
effects of AT on both adherence and adherence attitudes
in addition to psychiatric symptoms at 3-month follow-
up. One of the main reasons for not observing a signifi-
cant effect on adherence in this review might be the
widely recognised difficulty in objectively measuring pa-
tients’ treatment adherence [37]. Each of the three
reviewed studies that assessed adherence used a different
method none of which has been validated as superior to
others. Consequently, our finding might simply reflect
the questionable ability of adherence scales to objectively
measure this behaviour.
It is peculiar that an intervention focused on address-
ing adherence was found no better than usual care in
improving adherence or patients’ attitudes to taking their
medication. One reason for this observation might be
that the trials were not designed with sufficient power to
measure subtle changes in adherence behaviours and at-
titudes. This review provides outcome information
which could be used in future studies as a basis for
power calculations allowing identification of improve-
ments in adherence and attitudes. Another factor con-
tributing to our finding might be a ceiling effect due to
inclusion of mostly adherent patients in Gray et al. [5]
and Schulz et al. [20] and ‘highly motivated’ although
non-adherent patients in Chien et al. [18]. Patients in
other trials were reported having generally positive atti-
tudes or satisfaction with medication [19, 21] and [26].
As a result, a ceiling effect might have occurred, allow-
ing little room for improvement of adherence in these
patients. This observation is consistent with the findings
of a review of interventions addressing adherence by
Fig. 5 Comparison of the effects of the AT and TAU on adherence attitudes
Fig. 6 Comparison of the effects of the AT and TAU on adherence behaviours
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Barkhof et al. [38] who suggested that recruiting moder-
ately adherent patients might not provide sufficient po-
tential for change. Conversely, motivated patients might
be more likely to improve adherence to treatment after
receiving a psychological person-centred intervention
such as AT. Adherent and highly motivated patients are
not representative of the population of schizophrenia
patients [3]. Future trials should focus on recruiting
primarily non-adherent patients.
Another interesting finding is that little effects of AT on
adherence attitudes and behaviours were observed even in
studies that reported significant improvement in negative
symptoms and functioning, e.g. Chien et al. [18]. This ob-
servation might be explained by the intervention’s mech-
anism of actions, as targeted minor changes in attitudes or
behaviour might potentially have an exponential influence
on symptom improvement. Alternatively, AT might have
an empowering effect on patients through the use of CBT
and MI therapeutic approaches inherent in AT, making
patients feel more in control of their illness. Patients’ func-
tioning and symptom control might improve as a result,
while adherence itself could actually be less important.
Future research should explore the mechanisms of the
effect of AT to explain such observations and to ensure
that the intervention can be applied in the most appropri-
ate circumstances.
Review limitations
This review had a few limitations. A relatively small num-
ber of randomised controlled studies have been con-
ducted, which used varying lengths of follow-up. Further
research is therefore required to allow generalisation of
these findings to wider and more diverse populations. The
trials included in this review used a variety of different
patient-reported measures for similar clinical outcomes
and therefore the results of pooled effect sizes should be
treated with caution. The exception to this is the measure-
ment of psychiatric symptoms, as the PANSS was used as
an outcome measure in five of the six included studies. A
further limitation is the underpowered sample size in one
of the studies that might increase its risk of Type II error.
Conclusions
This review provides evidence that adherence therapy can
effectively improve patients’ psychiatric symptoms when
provided by trained professionals in combination with
usual care. It should be noted that although AT did not
result in the recommended 20 % reduction in PANSS
scores, it can be beneficial to patients when provided in
addition to usual antipsychotic treatment. We suggest that
patients with schizophrenia would benefit from receiving
AT as an adjunct therapy, especially if they have exhibited
positive attitudes or moderate adherence to medication.
The evidence on the effect of AT on patients’ adherence
behaviours and attitudes is limited at best and requires
further investigation.
While this brief psychological intervention based on
motivational interviewing has a potential to improve pa-
tient outcomes, it is unclear whether and how it could
be beneficial to non-adherent patients. Robust long-term
studies involving representative samples of patients
should be conducted with power calculations based on
the outcomes of this review, in order to allow exploring
the effects of AT on their adherence behaviours and
attitudes. Future research should also investigate the
therapeutic mechanisms of AT, specifically how the
intervention affects patients’ attitudes towards the illness
and its treatment and what the relationships are between
treatment attitudes, adherence behaviours and patient
functioning and symptoms. Improved understanding of
these mechanisms could explain why only minor im-
provements in these areas seemed to result in significant
reductions in psychiatric symptoms. Only one trial had a
control intervention (health education) that was not
TAU. Future research should, therefore, compare AT
with an appropriate placebo treatment delivered to non-
adherent patients.
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